SG Americas Securities
NAVB

SG Americas Securities’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

SG Americas Securities’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-4,861
Closed -$92K – 3180
2016
Q1 		$92K Buy
+4,861
New +$93.5K ﹤0.01% 2647
2015
Q4 		– Sell
-615
Closed -$28K – 3111
2015
Q3 		$28K Buy
+615
New +$23.2K ﹤0.01% 2000
2014
Q4 		– Sell
-7,677
Closed -$203K – 3462
2014
Q3 		$203K Buy
7,677
+4,304
+128% +$114K ﹤0.01% 1983
2014
Q2 		$100K Buy
3,373
+2,680
+387% +$86.7K ﹤0.01% 2341
2014
Q1 		$26K Buy
+693
New +$26.3K ﹤0.01% 2349
2013
Q4 		– Sell
-1,128
Closed -$60K – 3192
2013
Q3 		$60K Buy
+1,128
New +$65.8K ﹤0.01% 2771

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

SG Americas Securities's NAVB Position: Q2 2016 in Review

SG Americas Securities sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2016, closing a stake of 4,861 shares — an estimated $92K sold.

SG Americas Securities first reported a position in NAVB in Q3 2013 and held it in 6 quarters. The position peaked at $203K in Q3 2014. 63 funds tracked by Wall St. Rank hold NAVB as of Q2 2016.

  • SG Americas Securities reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2016 after selling out during the quarter.
  • SG Americas Securities sold 4,861 Navidea Biopharmaceuticals Inc. shares in Q2 2016, an estimated $92K.
  • SG Americas Securities first reported a position in Navidea Biopharmaceuticals Inc. in Q3 2013 and held it in 6 quarters.
  • SG Americas Securities's Navidea Biopharmaceuticals Inc. position peaked at $203K in Q3 2014.
  • 63 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2016.

Based on SG Americas Securities's 13F filing for Q2 2016, filed 3 Aug 2016.